Miyagi-Shiohira Chika, Kobayashi Naoya, Saitoh Issei, Watanabe Masami, Noguchi Yasufumi, Matsushita Masayuki, Noguchi Hirofumi
Department of Regenerative Medicine, Graduate School of Medicine, University of the Ryukyus , Okinawa , Japan.
† Okayama Saidaiji Hospital , Okayama , Japan.
Cell Med. 2016 Sep 1;9(1-2):15-20. doi: 10.3727/215517916X693122. eCollection 2017 Jan 8.
Adipose-derived mesenchymal stem cells (ASCs) have the potential to differentiate into cells of mesodermal origin, such as osteoblasts, adipocytes, myocytes, and chondrocytes, and cryopreservation is currently performed as a routine method for preserving ASCs to safely acquire large numbers of cells. For clinical application of ASCs, serum-free, xeno-free cryopreservation solutions should be used. This study determined the viability and adipo-osteogenic potential of cryopreserved ASCs using four cryopreservation solutions: 10% DMSO, Cell Banker 2 (serum free), Stem Cell Banker (=Cell Banker 3: serum free, xeno free), and TC protector (serum free, xeno free). The viability of the cryopreserved ASCs was over 80% with all cryopreservation solutions. No difference in the adipo-osteogenic potential was found between the cells that did or did not undergo cryopreservation in these cryopreservation solutions. These data suggest that Cell Banker 3 and TC protector are comparable with 10% DMSO and Cell Banker 2 for ASCs, and cryopreserved as well as noncryopreserved ASCs could be applied for regenerative medicine.
脂肪来源的间充质干细胞（ASCs）具有分化为中胚层来源细胞的潜力，如成骨细胞、脂肪细胞、肌细胞和软骨细胞，目前冷冻保存是一种保存ASCs的常规方法，以便安全地获取大量细胞。对于ASCs的临床应用，应使用无血清、无异种的冷冻保存溶液。本研究使用四种冷冻保存溶液：10%二甲基亚砜（DMSO）、细胞冻存液2（无血清）、干细胞冻存液（=细胞冻存液3：无血清、无异种）和TC保护剂（无血清、无异种），测定了冷冻保存的ASCs的活力和脂肪-成骨潜能。所有冷冻保存溶液处理的冷冻保存ASCs活力均超过80%。在这些冷冻保存溶液中，经过或未经过冷冻保存的细胞之间，脂肪-成骨潜能未发现差异。这些数据表明，对于ASCs，细胞冻存液3和TC保护剂与10% DMSO和细胞冻存液2相当，冷冻保存以及未冷冻保存的ASCs均可应用于再生医学。
